{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T02:55:29Z","timestamp":1772852129664,"version":"3.50.1"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T00:00:00Z","timestamp":1747699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T00:00:00Z","timestamp":1747699200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Sanofi Vaccines"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>A two-dose series of quadrivalent meningococcal conjugate vaccine (MenACWY) is recommended for the prevention of invasive meningococcal disease (IMD) in adolescents in the United States. In June 2024, the Advisory Committee on Immunization Practices discussed plans to review the adolescent meningococcal vaccination schedule. Various options are under consideration, including removing the first dose of MenACWY at age 11\u201312 years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>We evaluated the public health impact and cost-effectiveness of administering one or two doses of MenACWY compared to a scenario with no vaccination.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We constructed an incidence-based population model to compare costs and quality-adjusted life years (QALYs) associated with different vaccination schedules in a cohort of 11\u201325 year-olds, from a societal perspective, over a lifetime analytic horizon for outcomes related to death and disabilities. The main analyses compared various scenarios of MenACWY (Q) and MenB schedules to no vaccination. Further scenarios examined the impact of alternative assumptions applied to the first and\/or second dose of MenACWY.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Compared to no vaccination, 2 doses of MenACWY and 2 doses of MenB vaccine was projected to reduce IMD cases by 277 per year, resulting in an incremental cost-effectiveness ratio (ICER) of $625,322\/QALY. Administering 2 doses of MenACWY was projected to reduce the annual number of IMD cases by 275 at an ICER of $438,948\/QALY, which increased to 631 at an ICER of $190,030\/QALY when herd immunity was considered. Alternatively, if only 1 dose of MenACWY was administered, the reduction in cases would be 253 if administered at 11\u201312 years old and 125 if given at 16 years, with ICERs of $252,249 per QALY and $352,169\/QALY, respectively. Assuming a 25% increase in vaccination coverage rate, one MenACWY dose at 16 years resulted in 156 cases avoided.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The two doses of MenACWY that are currently recommended play a crucial role in reducing the burden of IMD and the first dose contributes significantly (\u2265\u200990%) to this reduction. It is essential to take this finding into account when considering any updates to the adolescent meningococcal vaccination schedule in the United States.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12889-025-21953-8","type":"journal-article","created":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T05:50:40Z","timestamp":1747720240000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Understanding the value of meningococcal vaccination for adolescents and young adults in the United States: insights from a steady-state modelling approach"],"prefix":"10.1186","volume":"25","author":[{"given":"E.","family":"Langevin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Robertson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Galarza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Dogu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Cristeau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Clay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Shin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,20]]},"reference":[{"key":"21953_CR1","unstructured":"Meningococcal Disease. Signs and Symptoms [https:\/\/www.cdc.gov\/meningococcal\/about\/symptoms.html]"},{"key":"21953_CR2","unstructured":"Meningococcal Disease. Causes and How It Spreads [https:\/\/www.cdc.gov\/meningococcal\/about\/causes-transmission.html]"},{"issue":"12","key":"21953_CR3","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/S1473-3099(10)70251-6","volume":"10","author":"H Christensen","year":"2010","unstructured":"Christensen H, May M, Bowen L, Hickman M, Trotter CL. Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect Dis. 2010;10(12):853\u201361.","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"21953_CR4","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s40121-021-00546-z","volume":"11","author":"J Shen","year":"2022","unstructured":"Shen J, Bou\u00e9e S, Aris E, Emery C, Beck EC. Long-term mortality and State Financial support in Invasive Meningococcal Disease\u2014Real-World Data Analysis using the French National Claims Database (SNIIRAM). Infect Dis Therapy. 2022;11(1):249\u201362.","journal-title":"Infect Dis Therapy"},{"key":"21953_CR5","unstructured":"Meningitis, Symptoms. [https:\/\/www.who.int\/health-topics\/meningitis#tab=tab_2]"},{"issue":"4","key":"21953_CR6","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s40121-018-0213-2","volume":"7","author":"KJ Olbrich","year":"2018","unstructured":"Olbrich KJ, M\u00fcller D, Schumacher S, Beck E, Meszaros K, Koerber F. Systematic review of Invasive Meningococcal Disease: Sequelae and Quality of Life Impact on patients and their caregivers. Infect Dis Ther. 2018;7(4):421\u201338.","journal-title":"Infect Dis Ther"},{"key":"21953_CR7","unstructured":"Meningococcal Disease, Surveillance. [https:\/\/www.cdc.gov\/meningococcal\/php\/surveillance\/?CDC_AAref_Val=https:\/\/www.cdc.gov\/meningococcal\/surveillance\/index.html]"},{"key":"21953_CR8","unstructured":"Emergency Preparedness and Response. Increase in Invasive Serogroup Y Meningococcal Disease in the United States [https:\/\/emergency.cdc.gov\/han\/2024\/han00505.asp]"},{"issue":"6","key":"21953_CR9","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1001\/jama.286.6.694","volume":"286","author":"LH Harrison","year":"2001","unstructured":"Harrison LH, Pass MA, Mendelsohn AB, Egri M, Rosenstein NE, Bustamante A, Razeq J, Roche JC. Invasive meningococcal disease in adolescents and young adults. JAMA. 2001;286(6):694\u20139.","journal-title":"JAMA"},{"key":"21953_CR10","unstructured":"National Center for Immunization and Respiratory Diseases: Enhanced Meningococcal Disease Surveillance report. 2019. In: Enhanced Meningococcal Disease Surveillance report. Edited by CDC; 2019."},{"key":"21953_CR11","unstructured":"National Center for Immunization and Respiratory Diseases: Enhanced Meningococcal Disease Surveillance report. 2020. In: Enhanced Meningococcal Disease Surveillance report. Edited by CDC; 2020."},{"key":"21953_CR12","unstructured":"National Center for Immunization and Respiratory Diseases: Enhanced Meningococcal Disease Surveillance report. 2021. In: Enhanced Meningococcal Disease Surveillance report. Edited by CDC; 2021."},{"key":"21953_CR13","unstructured":"National Center for Immunization and Respiratory Diseases: Enhanced Meningococcal Disease Surveillance report. 2022. In: Enhanced Meningococcal Disease Surveillance report. Edited by CDC; 2022."},{"key":"21953_CR14","unstructured":"Types of Meningococcal Vaccines. [https:\/\/www.cdc.gov\/meningococcal\/vaccines\/types.html]"},{"issue":"33","key":"21953_CR15","doi-asserted-by":"publisher","first-page":"5194","DOI":"10.1016\/j.vaccine.2020.06.013","volume":"38","author":"MS Dhingra","year":"2020","unstructured":"Dhingra MS, Peterson J, Hedrick J, Pan J, Neveu D, Jordanov E. Immunogenicity, safety and inter-lot consistency of a meningococcal conjugate vaccine (MenACYW-TT) in adolescents and adults: a phase III randomized study. Vaccine. 2020;38(33):5194\u2013201.","journal-title":"Vaccine"},{"issue":"19","key":"21953_CR16","doi-asserted-by":"publisher","first-page":"3560","DOI":"10.1016\/j.vaccine.2020.03.017","volume":"38","author":"L-J Chang","year":"2020","unstructured":"Chang L-J, Hedrick J, Christensen S, Pan J, Jordanov E, Dhingra MS. A phase II, randomized, immunogenicity and safety study of a quadrivalent meningococcal conjugate vaccine, MenACYW-TT, in healthy adolescents in the United States. Vaccine. 2020;38(19):3560\u20139.","journal-title":"Vaccine"},{"issue":"3","key":"21953_CR17","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1038\/s41390-023-02478-5","volume":"94","author":"B Zambrano","year":"2023","unstructured":"Zambrano B, Peterson J, Deseda C, Julien K, Spiegel CA, Seyler C, Simon M, Hoki R, Anderson M, Brabec B, et al. Quadrivalent meningococcal tetanus toxoid-conjugate booster vaccination in adolescents and adults: phase III randomized study. Pediatr Res. 2023;94(3):1035\u201343.","journal-title":"Pediatr Res"},{"issue":"34","key":"21953_CR18","doi-asserted-by":"publisher","first-page":"912","DOI":"10.15585\/mmwr.mm7234a3","volume":"72","author":"C Pingali","year":"2023","unstructured":"Pingali C, Yankey D, Elam-Evans LD, Markowitz LE, Valier MR, Fredua B, Crowe SJ, DeSisto CL, Stokley S, Singleton JA. Vaccination Coverage among adolescents aged 13\u201317 years - National Immunization Survey-Teen, United States, 2022. MMWR Morb Mortal Wkly Rep. 2023;72(34):912\u20139.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"15","key":"21953_CR19","doi-asserted-by":"publisher","first-page":"345","DOI":"10.15585\/mmwr.mm7315a4","volume":"73","author":"JP Collins","year":"2024","unstructured":"Collins JP, Crowe SJ, Ortega-Sanchez IR, Bahta L, Campos-Outcalt D, Loehr J, Morgan RL, Poehling KA, McNamara LA. Use of the Pfizer Pentavalent Meningococcal Vaccine among persons aged\u2009\u2265\u200910 years: recommendations of the Advisory Committee on Immunization Practices - United States, 2023. MMWR Morb Mortal Wkly Rep. 2024;73(15):345\u201350.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"21953_CR20","unstructured":"Revising the Adolescent Meningococcal Vaccine Schedule. Term of Reference and Considerations [https:\/\/stacks.cdc.gov\/view\/cdc\/148680]"},{"key":"21953_CR21","unstructured":"Work Group Considerations Regarding MenABCWY Vaccine and Discussion of Potential Risk Groups. for MenB Vaccination [https:\/\/stacks.cdc.gov\/view\/cdc\/157876]"},{"key":"21953_CR22","unstructured":"Child. and Adolescent Immunization Schedule by Age [https:\/\/www.cdc.gov\/vaccines\/schedules\/hcp\/imz\/child-adolescent.html]"},{"issue":"12","key":"21953_CR23","first-page":"1","volume":"72","author":"E Arias","year":"2023","unstructured":"Arias E, Xu J, Kochanek K. United States Life Tables, 2021. Natl Vital Stat Rep. 2023;72(12):1\u201364.","journal-title":"Natl Vital Stat Rep"},{"key":"21953_CR24","unstructured":"American Community Survey. [https:\/\/data.census.gov\/table\/ACSDP5Y2022.DP05?q=United%20States&g=010XX00US]"},{"key":"21953_CR25","unstructured":"Population and Housing Unit Estimates Datasets. [https:\/\/www.census.gov\/programs-surveys\/popest\/data\/data-sets.2000.List_1725564412.html]"},{"key":"21953_CR26","unstructured":"The Cost-effectiveness of a Potential Pentavalent Meningococcal Conjugate Vaccine. (Men ABCWY) versus the current men ACWY and men B vaccines for US adolescents [https:\/\/stacks.cdc.gov\/view\/cdc\/130162]"},{"key":"21953_CR27","doi-asserted-by":"crossref","unstructured":"Shepard CW, Ortega-Sanchez IR, Scott RD 2nd, Rosenstein NE. Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States. Pediatrics. 2005;115(5):1220\u201332.","DOI":"10.1542\/peds.2004-2514"},{"issue":"1","key":"21953_CR28","doi-asserted-by":"publisher","first-page":"96","DOI":"10.4161\/hv.7.1.13692","volume":"7","author":"KL Davis","year":"2011","unstructured":"Davis KL, Misurski D, Miller JM, Bell TJ, Bapat B. Cost of acute hospitalization and post-discharge follow-up care for meningococcal disease in the US. Hum Vaccin. 2011;7(1):96\u2013101.","journal-title":"Hum Vaccin"},{"issue":"7385","key":"21953_CR29","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1136\/bmj.326.7385.365","volume":"326","author":"ME Ramsay","year":"2003","unstructured":"Ramsay ME, Andrews NJ, Trotter CL, Kaczmarski EB, Miller E. Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. BMJ. 2003;326(7385):365\u20136.","journal-title":"BMJ"},{"key":"21953_CR30","unstructured":"CDC Vaccine Price List, Updated. April 2, 2024 [https:\/\/archive.cdc.gov\/#\/details?url=https:\/\/www.cdc.gov\/vaccines\/programs\/vfc\/awardees\/vaccine-management\/price-list\/2024\/2024-04-01.html]"},{"key":"21953_CR31","unstructured":"Economics of Potential Pentavalent Meningococcal Conjugate Vaccine (MenABCWY) versus the CurrentMenACWYand MenBvaccines for US Adolescents. October 23rd, 2023. https:\/\/www.cdc.gov\/acip\/downloads\/slides-2023-10-25-26\/03-Meningococcal-Ortega-Sanchez-508.pdf"},{"issue":"6","key":"21953_CR32","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1080\/13696998.2018.1542520","volume":"22","author":"SD Grosse","year":"2019","unstructured":"Grosse SD, Krueger KV, Pike J. Estimated annual and lifetime labor productivity in the United States, 2016: implications for economic evaluations. J Med Econ. 2019;22(6):501\u20138.","journal-title":"J Med Econ"},{"issue":"1","key":"21953_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1086\/524041","volume":"46","author":"IR Ortega-Sanchez","year":"2008","unstructured":"Ortega-Sanchez IR, Meltzer MI, Shepard C, Zell E, Messonnier ML, Bilukha O, Zhang X, Stephens DS, Messonnier NE. Economics of an adolescent meningococcal conjugate vaccination catch-up campaign in the United States. Clin Infect Dis. 2008;46(1):1\u201313.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"21953_CR34","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s11136-020-02650-y","volume":"30","author":"R Jiang","year":"2021","unstructured":"Jiang R, Janssen MFB, Pickard AS. US population norms for the EQ-5D-5L and comparison of norms from face-to-face and online samples. Qual Life Res. 2021;30(3):803\u201316.","journal-title":"Qual Life Res"},{"issue":"19","key":"21953_CR35","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1016\/j.vaccine.2016.03.020","volume":"34","author":"H Lecocq","year":"2016","unstructured":"Lecocq H, Parent du Ch\u00e2telet I, Taha MK, L\u00e9vy-Bruhl D, Dervaux B. Epidemiological impact and cost-effectiveness of introducing vaccination against serogroup B meningococcal disease in France. Vaccine. 2016;34(19):2240\u201350.","journal-title":"Vaccine"},{"issue":"6","key":"21953_CR36","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1007\/s11136-004-7706-z","volume":"14","author":"I Koomen","year":"2005","unstructured":"Koomen I, Raat H, Jennekens-Schinkel A, Grobbee DE, Roord JJ, van Furth M. Academic and behavioral limitations and health-related quality of life in school-age survivors of bacterial meningitis. Qual Life Res. 2005;14(6):1563\u201372.","journal-title":"Qual Life Res"},{"issue":"4","key":"21953_CR37","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.jinf.2010.07.006","volume":"61","author":"B Schmand","year":"2010","unstructured":"Schmand B, de Bruin E, de Gans J, van de Beek D. Cognitive functioning and quality of life nine years after bacterial meningitis. J Infect. 2010;61(4):330\u20134.","journal-title":"J Infect"},{"issue":"7","key":"21953_CR38","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1038\/s41390-019-0354-3","volume":"85","author":"P Hotez","year":"2019","unstructured":"Hotez P. America and Europe\u2019s new normal: the return of vaccine-preventable diseases. Pediatr Res. 2019;85(7):912\u20134.","journal-title":"Pediatr Res"},{"issue":"1","key":"21953_CR39","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1186\/s12889-024-19081-w","volume":"24","author":"K Schley","year":"2024","unstructured":"Schley K, Jodar E, Presa JV, Willis SJ, Prener CG. The impact of regional disparities on the availability of meningococcal vaccines in the US. BMC Public Health. 2024;24(1):1771.","journal-title":"BMC Public Health"},{"issue":"2","key":"21953_CR40","doi-asserted-by":"publisher","first-page":"S72","DOI":"10.1016\/j.acap.2018.01.002","volume":"18","author":"CM Rand","year":"2018","unstructured":"Rand CM, Goldstein NPN. Patterns of primary care physician visits for US adolescents in 2014: implications for vaccination. Acad Pediatr. 2018;18(2):S72\u20138.","journal-title":"Acad Pediatr"},{"issue":"3","key":"21953_CR41","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.jpeds.2013.10.042","volume":"164","author":"Y Tsai","year":"2014","unstructured":"Tsai Y, Zhou F, Wortley P, Shefer A, Stokley S. Trends and characteristics of preventive care visits among commercially insured adolescents, 2003\u20132010. J Pediatr. 2014;164(3):625\u201330.","journal-title":"J Pediatr"},{"issue":"3","key":"21953_CR42","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.jadohealth.2016.10.005","volume":"60","author":"SK Harris","year":"2017","unstructured":"Harris SK, Aalsma MC, Weitzman ER, Garcia-Huidobro D, Wong C, Hadland SE, Santelli J, Park MJ, Ozer EM. Research on clinical preventive services for adolescents and young adults: where are we and where do we need to go? J Adolesc Health. 2017;60(3):249\u201360.","journal-title":"J Adolesc Health"},{"issue":"2","key":"21953_CR43","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1080\/20477724.2021.1972663","volume":"116","author":"F Martinon-Torres","year":"2022","unstructured":"Martinon-Torres F, Taha MK, Knuf M, Abbing-Karahagopian V, Pellegrini M, Bekkat-Berkani R, Abitbol V. Evolving strategies for meningococcal vaccination in Europe: overview and key determinants for current and future considerations. Pathog Glob Health. 2022;116(2):85\u201398.","journal-title":"Pathog Glob Health"},{"issue":"9320","key":"21953_CR44","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1016\/S0140-6736(02)08679-8","volume":"359","author":"MC Maiden","year":"2002","unstructured":"Maiden MC, Stuart JM. Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination. Lancet. 2002;359(9320):1829\u201331.","journal-title":"Lancet"},{"issue":"4","key":"21953_CR45","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1080\/00325481.2021.1876478","volume":"134","author":"L Huang","year":"2022","unstructured":"Huang L, Snedecor SJ, Balmer P, Srivastava A. Potential public health impact of a Neisseria meningitidis A, B, C, W, and Y pentavalent vaccine in the United States. Postgrad Med. 2022;134(4):341\u20138.","journal-title":"Postgrad Med"},{"issue":"7","key":"21953_CR46","doi-asserted-by":"publisher","first-page":"e203","DOI":"10.1097\/INF.0000000000001512","volume":"36","author":"P De Wals","year":"2017","unstructured":"De Wals P, Zhou Z. Cost-effectiveness comparison of Monovalent C Versus Quadrivalent ACWY Meningococcal Conjugate Vaccination in Canada. Pediatr Infect Dis J. 2017;36(7):e203\u20137.","journal-title":"Pediatr Infect Dis J"},{"issue":"5","key":"21953_CR47","doi-asserted-by":"publisher","first-page":"e0175721","DOI":"10.1371\/journal.pone.0175721","volume":"12","author":"TE Delea","year":"2017","unstructured":"Delea TE, Weycker D, Atwood M, Neame D, Alvarez FP, Forget E, Langley JM, Chit A. Cost-effectiveness of alternate strategies for childhood immunization against meningococcal disease with monovalent and quadrivalent conjugate vaccines in Canada. PLoS ONE. 2017;12(5):e0175721.","journal-title":"PLoS ONE"},{"issue":"5","key":"21953_CR48","doi-asserted-by":"publisher","first-page":"e65036","DOI":"10.1371\/journal.pone.0065036","volume":"8","author":"H Hepkema","year":"2013","unstructured":"Hepkema H, Pouwels KB, Van Der Ende A, Westra TA, Postma MJ. Meningococcal serogroup A, C, W135 and Y conjugated vaccine: a cost-effectiveness analysis in the Netherlands. PLoS ONE. 2013;8(5):e65036.","journal-title":"PLoS ONE"},{"issue":"35","key":"21953_CR49","doi-asserted-by":"publisher","first-page":"5009","DOI":"10.1016\/j.vaccine.2019.07.008","volume":"37","author":"S Si","year":"2019","unstructured":"Si S, Zomer E, Fletcher S, Lee J, Liew D. Cost-effectiveness of meningococcal polysaccharide serogroups a, C, W-135 and Y conjugate vaccine in Australian adolescents. Vaccine. 2019;37(35):5009\u201315.","journal-title":"Vaccine"},{"issue":"1","key":"21953_CR50","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jval.2020.09.004","volume":"24","author":"E Beck","year":"2021","unstructured":"Beck E, Klint J, Neine M, Garcia S, Meszaros K. Cost-effectiveness of 4CMenB infant vaccination in England: a Comprehensive Valuation considering the broad impact of Serogroup B Invasive Meningococcal Disease. Value Health. 2021;24(1):91\u2013104.","journal-title":"Value Health"},{"issue":"1","key":"21953_CR51","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1080\/21645515.2019.1632679","volume":"16","author":"WY Cheng","year":"2020","unstructured":"Cheng WY, Chang R, Novy P, O\u2019Connor C, Duh MS, Hogea CS. Determinants of Meningococcal ACWY vaccination in adolescents in the US: completion and compliance with the CDC recommendations. Hum Vaccin Immunother. 2020;16(1):176\u201388.","journal-title":"Hum Vaccin Immunother"},{"issue":"5","key":"21953_CR52","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1080\/14760584.2022.2052048","volume":"21","author":"MK Taha","year":"2022","unstructured":"Taha MK, Martinon-Torres F, Kollges R, Bonanni P, Safadi MAP, Booy R, Smith V, Garcia S, Bekkat-Berkani R, Abitbol V. Equity in vaccination policies to overcome social deprivation as a risk factor for invasive meningococcal disease. Expert Rev Vaccines. 2022;21(5):659\u201374.","journal-title":"Expert Rev Vaccines"},{"issue":"1","key":"21953_CR53","doi-asserted-by":"publisher","first-page":"2406613","DOI":"10.1080\/21645515.2024.2406613","volume":"20","author":"S Begum","year":"2024","unstructured":"Begum S, Herrera-Restrepo O, Rolland C, Purushotham S, Andani A, Shah H, Kocaata Z. Inequalities in the risk and prevention of invasive meningococcal disease in the United States - A systematic literature review. Hum Vaccin Immunother. 2024;20(1):2406613.","journal-title":"Hum Vaccin Immunother"},{"issue":"7","key":"21953_CR54","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1093\/cid\/ciab358","volume":"73","author":"CC Potts","year":"2021","unstructured":"Potts CC, Retchless AC, McNamara LA, Marasini D, Reese N, Swint S, Hu F, Sharma S, Blain AE, Lonsway D, et al. Acquisition of Ciprofloxacin Resistance among an expanding clade of beta-Lactamase-Positive, Serogroup Y Neisseria meningitidis in the United States. Clin Infect Dis. 2021;73(7):1185\u201393.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"21953_CR55","doi-asserted-by":"publisher","first-page":"99","DOI":"10.15585\/mmwr.mm7305a2","volume":"73","author":"I Berry","year":"2024","unstructured":"Berry I, Rubis AB, Howie RL, Sharma S, Marasini D, Marjuki H, Crowe S, McNamara LA. Selection of antibiotics as Prophylaxis for Close contacts of patients with Meningococcal Disease in Areas with Ciprofloxacin Resistance \u2014 United States, 2024. Morb Mortal Wkly Rep. 2024;73(5):99\u2013103.","journal-title":"Morb Mortal Wkly Rep"},{"key":"21953_CR56","unstructured":"Estimating the impact of vaccines in. reducing antimicrobial resistance and antibiotic use: technical report [https:\/\/iris.who.int\/bitstream\/handle\/10665\/379116\/9789240098787-eng.pdf?sequence=1]"}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-025-21953-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12889-025-21953-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-025-21953-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T05:50:49Z","timestamp":1747720249000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpublichealth.biomedcentral.com\/articles\/10.1186\/s12889-025-21953-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,20]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["21953"],"URL":"https:\/\/doi.org\/10.1186\/s12889-025-21953-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5084908\/v1","asserted-by":"object"}]},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,20]]},"assertion":[{"value":"13 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"EL, CR, KG, AD, and TS are employees of Sanofi and may hold stock or stock options. JW currently holds a co-sponsored Industrial Research Chair grant with Sanofi. OC and EC are employees of Clever-Access, a consultancy that received funding from Sanofi to conduct this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1863"}}